Compare AbbVie Inc (ABBV) vs Vanguard Value Index Fund ETF (VTV) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

VTV trades at $219.57 with a slight 0.18% daily gain, showing strong 2026 performance with a 16% year-to-date return. Technical indicators signal bullish momentum with moving averages strongly positive, while oscillators remain neutral. The ETF benefits from market rotation away from tech stocks toward value investments, with recent news highlighting its defensive positioning amid Fed policy uncertainty and AI bubble concerns.

VTV offers exposure to large-cap value stocks with minimal tech concentration, providing diversification benefits as markets shift from growth to value. Key risks include Fed rate hike sensitivity and macroeconomic volatility, though the ETF's low 0.03% expense ratio and value focus position it well for continued rotation trends. Analyst sentiment is mixed with some caution about limited upside potential.